StockData
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX) income statement

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)

Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%

Nurix Therapeutics, Inc. income statement

Ratios

Latest available, balances at Aug 31, 2026

Profitability, TTM

Gross margin
–
Operating margin
41.3%
Net margin
42.0%
Return on equity, FY2025
-49.6%

Financial strength

Current ratio
8.44
Debt to equity
–
Debt to assets
–
Cash to current liabilities
550.9%

Valuation

P/E ratio
6.2
Price to sales
2.22
Price to book
1.61
Dividend yield
0.00%

See a number that looks wrong?